Michael C. Soulen, MD

Professor
Abramson Cancer Center, University of Pennsylvania, United States

Presentation(s):

• Randomized Embolization Trial for NeuroEndocrine Tumors (RETNET)

  Sunday, March 30, 2025
  3:54 PM – 4:03 PM CT

• 70 - Utility of Alpha-Fetoprotein (AFP) monitoring after Y-90 radioembolization of hepatocellular carcinoma in non-AFP producers

  Monday, March 31, 2025
  12:10 PM – 1:10 PM CT

• Rapid Sequence Bland Embolization in the Treatment of Neuroendocrine Tumors with Large Volume Hepatic Metastatic Disease

  Monday, March 31, 2025
  4:03 PM – 4:12 PM CT

• In Vivo Evaluation of Spectral CT Thermometry for Non-invasive, Real-time Temperature Monitoring of Thermal Ablation

  Tuesday, April 1, 2025
  3:27 PM – 3:36 PM CT

• Identification of Novel Pathogenic Deletions in NET Liver Metastases with Implications for TACE Therapy

  Tuesday, April 1, 2025
  3:36 PM – 3:45 PM CT

• Lipiodol Deposition in NET Liver Metastases during TACE using Pressure-Enabled versus Endhole Catheters: Pilot Data from a Randomized, Internally-Controlled Trial

  Tuesday, April 1, 2025
  3:54 PM – 4:03 PM CT

• Pilot Randomized Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients Awaiting Transplantation

  Tuesday, April 1, 2025
  4:12 PM – 4:21 PM CT

• Premedication with NK-1 antagonists and COX-2 inhibitors improves same day discharge rates following chemoembolization for hepatocellular carcinoma and neuroendocrine liver metastasis

  Tuesday, April 1, 2025
  4:21 PM – 4:30 PM CT

• Associations between patterns of neuroendocrine liver metastatic burden and outcomes after liver-directed therapy, systemic chemotherapy and systemic radiotherapy.

  Tuesday, April 1, 2025
  3:36 PM – 3:45 PM CT